Leads Biolabs-B (09887.HK) Partner Oblenio Closes Oversubscribed $62M Series B Led by Pfizer Ventures

Nanjing Leads Biolabs Co., Ltd. (9887.HK) announced on June 25, 2026, that the Company is pleased to announce that Oblenio Bio ("Oblenio"), its joint venture with Aditum Bio, has successfully completed an oversubscribed Series B financing of $62 million. The Series B was led by Pfizer Ventures, with participation from Deep Track Capital, GV and Oblenio's founding investor Aditum Bio. This milestone will significantly advance the clinical development of LBL-051. LBL-051, as Oblenio's sole asset, is a CD19/BCMA/CD3 tri-specific T-cell engager antibody designed to provide a novel treatment option for patients with severe autoimmune diseases through immune reset.

Developed using the Company's proprietary LeadsBodyTM platform, LBL-051 simultaneously targets BCMA, CD19 and CD3, enabling broader clearance of pathogenic B cells and plasma cells, with the potential to achieve deeper and more durable responses compared to mono-specific or bispecific antibodies. This immune reset strategy aims to help patients with refractory autoimmune diseases achieve long-term drug-free remission.

Oblenio recently presented preclinical data at the 2026 European Congress of Rheumatology (EULAR 2026) showing that LBL-051 achieved complete clearance of peripheral blood and tissue B cells and plasma cells in non-human primate models through stepwise dosing, with immature non-memory B cells appearing during the recovery phase. This immunological profile is consistent with clinical observations in autoimmune disease patients who have achieved long-term drug-free remission. Importantly, the study showed that treatment did not trigger cytokine release syndrome (CRS) even at higher exposure levels, while peripheral blood immunoglobulins showed dose-dependent decreases consistent with plasma cell clearance effects. Based on these data, Oblenio is rapidly advancing toward clinical trial initiation.

Following the completion of the Series B financing, the Company's founder, Chairman and CEO Dr. Kang Xiaoqiang will serve as an observer on Oblenio's Board of Directors, further deepening the strategic partnership. As the original developer of LBL-051, the Company will continue to provide technical support to Oblenio and is entitled to milestone payments and sales royalties in the global clinical development and commercialization of LBL-051.

Prior to the Series B financing, the Company indirectly held a 10% equity stake in Oblenio. As Oblenio is not a subsidiary of the Company, the deemed disposal does not constitute a transaction under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.